Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Subscribe To Our Newsletter & Stay Updated
